About PharmaPendium - Preclinical and Clinical Safety Data
PharmaPendium accelerates drug development
From candidate assessment to regulatory applications
Thanks to the unique crucial comparative safety data and access to regulatory precedents, PharmaPendium lets you make informed drug candidate assessments and accelerate the development and approval processes.
What does PharmaPendium offer?
Access to unique comparative drug safety data
PharmaPendium is the only research solution that brings together excerpted preclinical, clinical and post-release safety data into a single longitudinal database and offers regulatory context with 2.2 million searchable pages of FDA approval packages. This extensive drug discovery content also includes EMA EPARs, historical data, and preclinical studies that have not been published anywhere else.
Insight into your search results
Dedicated features support the analysis and assessment of results obtained from in vitro and in vivo tests and comparisons with approved drugs and targets. You can also compare adverse effects and species specificity across drugs and drug classes. PharmaPendium helps you decide on necessary secondary testing and understand potential risks.
Drug development data delivered your way
Key features include text searching with synonym recognition; structure searching with structure similarity and substructure options; and browsing by drug name, class or target, or by adverse effect and toxicity. You choose how you want to search the data and filter your results.
Compatibility with other research solutions
PharmaPendium is compatible with other members of the Elsevier Life Science Solutions Portfolio, including Reaxys Medicinal Chemistry, the Reaxys Chemistry Discovery Engine and Pathway Studio. This interoperability lets you access even more information about your drug candidate, its interactions with other compounds, and its behavior in vivo.
Increase your access to regulatory documents
The optional Pharmacokinetics Module allows even greater access to preclinical and clinical exposure data extracted from the entire history of FDA Approval Packages and EMA documents.
Reveal drug-metabolizing enzyme and transporter effects
The optional Metabolizing Enzymes and Transporters Module is a major resource for the modeling of adverse reactions that result from the effects of drug-metabolizing enzymes and transporters.